Michael J. Millward

机构：Health Net, SA Health

发表论文 77 篇 · 总被引 7009 次 · h-index 28

代表论文

• Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial (2012 · The Lancet · 被引 3013)
• BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF -Mutant Thyroid Cancer (2014 · Thyroid · 被引 232)
• Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial (2014 · The Lancet Oncology · 被引 132)
• An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). (2013 · Journal of Clinical Oncology · 被引 113)
• Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR (2014 · Clinical Biochemistry · 被引 112)
• Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials (2020 · European Journal of Cancer · 被引 69)